Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,484
  • Shares Outstanding, K 1,034
  • Annual Sales, $ 1,920 K
  • Annual Income, $ -31,540 K
  • 60-Month Beta 1.15
  • Price/Sales 8.05
  • Price/Cash Flow N/A
  • Price/Book 1.64
Trade AVTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.18
  • Number of Estimates 1
  • High Estimate -1.18
  • Low Estimate -1.18
  • Prior Year -202.38
  • Growth Rate Est. (year over year) +99.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.10 +52.07%
on 04/09/24
22.47 -24.88%
on 04/01/24
-4.87 (-22.39%)
since 03/28/24
3-Month
4.01 +320.94%
on 02/05/24
34.46 -51.02%
on 03/28/24
+12.11 (+253.88%)
since 01/29/24
52-Week
3.95 +327.33%
on 01/17/24
1,130.40 -98.51%
on 06/23/23
-681.52 (-97.58%)
since 04/28/23

Most Recent Stories

More News
Avalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue Estimates

Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 12.37% and 52.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

AVTX : 16.88 (+5.90%)
JAZZ : 111.22 (+1.61%)
Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVTX : 16.88 (+5.90%)
IONS : 41.99 (+0.96%)
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.

PCRX : 26.05 (-1.06%)
RCEL : 8.72 (+2.35%)
AVTX : 16.88 (+5.90%)
EQRX : 2.34 (-2.09%)
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal

Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.

NVO : 126.88 (+0.02%)
RCEL : 8.72 (+2.35%)
AVTX : 16.88 (+5.90%)
EQRX : 2.34 (-2.09%)
Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device

Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.

RHHBY : 30.3300 (+0.26%)
NVO : 126.88 (+0.02%)
LLY : 737.20 (+0.50%)
AVTX : 16.88 (+5.90%)
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate....

ALT : 6.39 (-11.91%)
RCEL : 8.72 (+2.35%)
AVTX : 16.88 (+5.90%)
EQRX : 2.34 (-2.09%)
ACER's Stock Down on Failure of Phase II Study, Cash Updates

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

SNY : 49.09 (-0.08%)
ACER : 0.6601 (-17.95%)
AZYO : 1.4900 (+2.05%)
AVTX : 16.88 (+5.90%)
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote

FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.

PFE : 25.64 (+0.94%)
NVO : 126.88 (+0.02%)
MRK : 130.12 (-0.82%)
AVTX : 16.88 (+5.90%)
Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

CPRX : 15.23 (+2.28%)
RCEL : 8.72 (+2.35%)
AZYO : 1.4900 (+2.05%)
AVTX : 16.88 (+5.90%)
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics

Origin Materials, Inc. (“Origin” and “Origin Materials”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable...

ORGN : 0.7638 (+8.42%)
ORGNW : 0.0444 (-10.84%)
AVTX : 16.88 (+5.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is...

See More

Key Turning Points

3rd Resistance Point 18.08
2nd Resistance Point 17.15
1st Resistance Point 16.55
Last Price 16.88
1st Support Level 15.01
2nd Support Level 14.08
3rd Support Level 13.48

See More

52-Week High 1,130.40
Fibonacci 61.8% 700.10
Fibonacci 50% 567.18
Fibonacci 38.2% 434.25
Last Price 16.88
52-Week Low 3.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar